Video Upload Options

References

1. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, McCarthy S,Fantin VR, Straley KS, Lobo S, Aston W, Green CL, Gale RE, Tirabosco R, FutrealA, Campbell P, Presneau N, Flanagan AM. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet. 2011 Nov6;43(12):1262-5. doi: 10.1038/ng.994.
2. Kranendijk M, Struys EA, Salomons GS, Van der Knaap MS, Jakobs C. Progress in understanding 2-hydroxyglutaric acidurias. J Inherit Metab Dis. 2012Jul;35(4):571-87. doi: 10.1007/s10545-012-9462-5.
3. Kranendijk M, Struys EA, van Schaftingen E, Gibson KM, Kanhai WA, van derKnaap MS, Amiel J, Buist NR, Das AM, de Klerk JB, Feigenbaum AS, Grange DK,Hofstede FC, Holme E, Kirk EP, Korman SH, Morava E, Morris A, Smeitink J, Sukhai RN, Vallance H, Jakobs C, Salomons GS. IDH2 mutations in patients withD-2-hydroxyglutaric aciduria. Science. 2010 Oct 15;330(6002):336. doi:10.1126/science.1192632.
4. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS,Root DE, Ebert BL, Kaelin WG Jr. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013 Mar29;339(6127):1621-5. doi: 10.1126/science.1231677.
5. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, KhaninR, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL,Mellinghoff IK, Thompson CB. IDH mutation impairs histone demethylation andresults in a block to cell differentiation. Nature. 2012 Feb 15;483(7390):474-8. doi: 10.1038/nature10860.
6. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J,Cleton-Jansen AM, van Oosterwijk JG, Verbeke SL, Meijer D, van Wezel T, Nord KH, Sangiorgi L, Toker B, Liegl-Atzwanger B, San-Julian M, Sciot R, Limaye N,Kindblom LG, Daugaard S, Godfraind C, Boon LM, Vikkula M, Kurek KC, Szuhai K,French PJ, Bovée JV. Somatic mosaic IDH1 and IDH2 mutations are associated withenchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet. 2011 Nov 6;43(12):1256-61. doi: 10.1038/ng.1004.
7. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer:alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010 Jul 7;102(13):932-41. doi: 10.1093/jnci/djq187.
8. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A,Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA,Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R,Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E,Cervantes F, Barosi G, Cazzola M, Cross NC, Tefferi A. Mutations and prognosis inprimary myelofibrosis. Leukemia. 2013 Sep;27(9):1861-9. doi:10.1038/leu.2013.119.
9. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR,Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB. The common feature of leukemia-associated IDH1 and IDH2mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to2-hydroxyglutarate. Cancer Cell. 2010 Mar 16;17(3):225-34. doi:10.1016/j.ccr.2010.01.020.
10. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I,Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D,Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765-73. doi:10.1056/NEJMoa0808710.
11. Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis:mechanistic insights and clinical perspectives. Clin Cancer Res. 2012 Oct15;18(20):5562-71. doi: 10.1158/1078-0432.CCR-12-1773. Review.